- |||||||||| tamoxifen / Generic mfg.
Clinical, Review, Journal: Clinical Trials for Ductal Carcinoma In Situ of the Breast. (Pubmed Central) - Sep 14, 2019 The use of pre-operative endocrine therapy has been evaluated in a recently completed trial of letrozole use in postmenopausal women with DCIS; and in on-going trials of tamoxifen, used either orally, or as a 4-hydroxytamoxifen gel formulation for application to the breast skin. This review summaries the major past and current clinical trials of DCIS, and the likely trajectories of DCIS management in the near future.
- |||||||||| metformin / generics
Clinical, Review, Journal: A Review of First Line Infertility Treatments and Supporting Evidence in Women with Polycystic Ovary Syndrome. (Pubmed Central) - Sep 13, 2019 In obese women with PCOS, clomiphene citrate could be used in preference to metformin alone whilst clomiphene citrate could be added to metformin alone in order to improve reproductive outcome in all women with PCOS. Gonadotrophins, which are more effective than clomiphene citrate in therapy naïve women with PCOS, can be considered a first line therapy in the presence of ultrasound monitoring, following counselling on the cost and the potential risk of multiple pregnancy.
- |||||||||| letrozole / Generic mfg., sorafenib / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (clinicaltrials.gov) - Sep 12, 2019 P1/2, N=54, Active, not recruiting, Gonadotrophins, which are more effective than clomiphene citrate in therapy naïve women with PCOS, can be considered a first line therapy in the presence of ultrasound monitoring, following counselling on the cost and the potential risk of multiple pregnancy. Trial completion date: May 2019 --> May 2021 | Trial primary completion date: May 2019 --> May 2021
- |||||||||| letrozole / Generic mfg., Megace (megestrol) / BMS, SOBI
ESR1 HOTSPOT MUTATIONS IN ENDOMETRIAL STROMAL SACROMAS MAY CONFER HORMONAL RESISTANCE (E-Poster Area (Americas)) - Sep 10, 2019 - Abstract #IGCS2019IGCS_148; Results Both patients received at least two lines of hormonal suppressive therapy including letrozole and megestrol. Our findings suggest that the ESR1 Y537S hotspot mutation in LGESS, either pre-existing or acquired, may be associated with endocrine resistance and/or high-grade transformation in these lesions.
- |||||||||| letrozole / generics
Review, Journal: Investigation and management of subfertility. (Pubmed Central) - Sep 5, 2019 ...Ovulation can be restored in women with PCOS using letrozole (an aromatase inhibitor), clomifene citrate (an oestrogen antagonist) or exogenous gonadotrophin administration...Unexplained subfertility can be treated with in vitro fertilisation after 2 years of trying to conceive. Involuntary childlessness is associated with significant psychological morbidity; hence, expert assessment and prompt treatment are necessary to support such couples.
- |||||||||| paclitaxel / Generic Mfg.
Clinical, Journal: Effective Neo-Adjuvant Chemotherapy and Hormonal Therapy for Invasive Micro-Papillary Carcinoma of the Breast-Two Case Reports (Pubmed Central) - Aug 30, 2019 ...The patient underwent 4 courses of EC(epirubicin 90mg/ m2, cyclophosphamide 600 mg/m2), followed by 4 courses of triweekly docetaxel and nab-paclitaxel chemotherapy...Pre-operative treatment consisted of letrozole(2.5mg/day)from May 2013 and hormone therapy for 6 months...Histopathologically, no remnant of IMPC component was observed apart from an 11mm papillo-tubular carcinoma. In spite of the fact that IMPC is considered highly malignant, pre-operative chemotherapy and hormonal therapy may be effective.
- |||||||||| Ibrance (palbociclib) / Pfizer
Clinical, Journal, BRCA Biomarker, PARP Biomarker: Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review. (Pubmed Central) - Aug 29, 2019 Overall, biological rationale, preclinical, and clinical data support the prominent role of CDK 4/6 inhibitors plus endocrine therapy, even in combination with PARP inhibitors, in the treatment of BRCA-mutated, ER-positive breast cancers. However, the interaction between Cyclin/CDK pathway, ER and BRCA is complex and evidences reported so far, albeit reliable, await confirmation in the context of future randomized clinical trials.
- |||||||||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion date, Trial primary completion date: Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors (clinicaltrials.gov) - Aug 29, 2019 P3, N=412, Recruiting, However, the interaction between Cyclin/CDK pathway, ER and BRCA is complex and evidences reported so far, albeit reliable, await confirmation in the context of future randomized clinical trials. Trial completion date: Jun 2017 --> Jun 2020 | Trial primary completion date: Jan 2017 --> Jan 2020
|